The company is betting that the alternative cytotoxic payload in its ADC can overcome resistance in patients who relapse on Enhertu.

New PICCOLO trial analyses showed that mirvetuximab soravtansine achieved 52% response rates and 27-month overall survival in ...

During a live event, Heather L. McArthur, MD, MPH, discussed the TAILORx trial in node-negative hormone ...

Industry veteran Catherine Owen Adams expects external innovation will be key to getting the brain-focused drug developer to “the next level.” ...

Datroway is used to treat an advanced form of non-small cell lung cancer in adults who had received prior treatment.

Rise in geriatric population; increase in healthcare expenditure; and increase in investments in R&D activities by various healthcare companies.” — Allied Market Research PORTLAND, IN, UNITED STATES, ...

AstraZeneca chief executive Pascal Soriot is considering moving the company's stock exchange listing from the UK to the US – ...

The Contrast Media Market is projected to grow at a CAGR of 5-6%. Key factors influencing the contrast media market include ...

A mum who has breast cancer is one of thousands of women who could be "missing out" on life-extending drugs because of the way they are assessed by the health service, a charity has warned. Breast ...

Thousands of women with advanced breast cancer could be denied life-extending drugs because of the "unfair" way they are ...

Bangalore: AstraZeneca Pharma India Limited has received permission from the Central Drugs Standard Control Organisation ...